ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
12.73
-0.48 (-3.63%)
At close: Nov 6, 2026, 4:00 PM EST
12.74
+0.01 (0.08%)
After-hours: Nov 6, 2026, 7:30 PM EST
ADMA Biologics Employees
As of December 31, 2025, ADMA Biologics had 647 total employees, including 640 full-time and 7 part-time employees. The number of employees decreased by 38 or 5.55% compared to the previous year. That makes ADMA Biologics the 18,091st largest employer in the world and 2,479th in the United States.
Employees
647
Change (1Y)
-38
Growth (1Y)
-5.55%
Revenue / Employee
$802,400
Profits / Employee
$281,937
Market Cap
2.82B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 647 | -38 | -5.55% | 640 | 7 |
| Dec 31, 2024 | 685 | 61 | 9.78% | 677 | 8 |
| Dec 31, 2023 | 624 | 7 | 1.13% | 624 | 0 |
| Dec 31, 2022 | 617 | 90 | 17.08% | 617 | 0 |
| Dec 31, 2021 | 527 | 120 | 29.48% | 527 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Arcus Biosciences | 601 |
| Recursion Pharmaceuticals | 600 |
| Beam Therapeutics | 540 |
| Biohaven | 274 |
| Xencor | 260 |
| Celldex Therapeutics | 198 |
| Pharvaris | 148 |
ADMA News
- 1 day ago - Adma Biologics rises 27.3% - TheFly
- 1 day ago - Adma Biologics rises 19.8% - TheFly
- 1 day ago - Adma Biologics price target raised to $18 from $17 at Mizuho - TheFly
- 1 day ago - Adma Biologics price target raised to $13 from $12 at Cantor Fitzgerald - TheFly
- 1 day ago - Adma Biologics price target raised to $19 from $18 at Canaccord - TheFly
- 2 days ago - Adma Biologics reports Q3 adjusted basic EPS 23c, consensus 20c - TheFly
- 2 days ago - Adma Biologics backs FY26 revenue view at least $530M, consensus $535.35M - TheFly
- 2 days ago - ADMA Biologics Earnings Call Transcript: Q3 2026 - Transcripts